Halozyme's PEGPH20 tagged an Orphan Drug in Europe

• The European Commission designates Halozyme Therapeutics' (NASDAQ:HALO +9.1%) PEGylated recombinant human hyaluronidase, PEGPH20, an Orphan Medicinal Product for the treatment of pancreatic cancer. Among the benefits of EMA Orphan status is a 10-year period of market exclusivity if approved.
• The FDA designated PEGPH20 an Orphan Drug for the same indication in October. If approved, it will have a seven-year period of market exclusivity in the U.S.
• PEGPH20 is currently in Phase 2 development.
• Previously: Halozyme +4.2% AH; cancer drug gets orphan designation (Oct. 2, 2014)
• Previously: Halozyme pancreatic cancer drug candidate Fast Track'd (Sept. 3, 2014)